Distribuzione geografica
Continente #
NA - Nord America 10606
EU - Europa 730
AS - Asia 212
Continente sconosciuto - Info sul continente non disponibili 5
SA - Sud America 5
OC - Oceania 4
Totale 11562
Nazione #
US - Stati Uniti d'America 10604
IE - Irlanda 256
CN - Cina 143
IT - Italia 134
DE - Germania 74
UA - Ucraina 69
FR - Francia 48
SE - Svezia 37
GB - Regno Unito 33
KR - Corea 30
FI - Finlandia 13
PL - Polonia 13
RU - Federazione Russa 13
ES - Italia 8
BE - Belgio 7
KG - Kirghizistan 7
CH - Svizzera 6
IN - India 6
NL - Olanda 6
AU - Australia 4
JP - Giappone 4
TR - Turchia 4
CL - Cile 3
EU - Europa 3
GR - Grecia 3
MY - Malesia 3
RO - Romania 3
TW - Taiwan 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AT - Austria 2
BD - Bangladesh 2
BR - Brasile 2
CA - Canada 2
DK - Danimarca 2
IR - Iran 2
SG - Singapore 2
SI - Slovenia 2
UZ - Uzbekistan 2
IL - Israele 1
KZ - Kazakistan 1
MN - Mongolia 1
NO - Norvegia 1
TH - Thailandia 1
Totale 11562
Città #
Wilmington 3189
Houston 2938
Woodbridge 1609
Fairfield 705
Chandler 340
Seattle 318
Ashburn 283
Cambridge 260
Dublin 237
Ann Arbor 205
Medford 166
Dearborn 93
Lawrence 79
Beijing 76
San Diego 55
Jacksonville 43
Rome 32
Zhengzhou 20
Menlo Park 18
Redwood City 17
Seoul 17
London 15
Perugia 15
Esslingen am Neckar 13
Falls Church 13
Kraków 13
Saint Petersburg 9
Shanghai 9
Brussels 7
Norwalk 7
Milan 6
Mountain View 6
Nanchang 5
Nanjing 5
Chicago 4
Guangzhou 4
Islington 4
Madrid 4
Renton 4
Sedico 4
Chengdu 3
Coushatta 3
Detroit 3
Hefei 3
Helsinki 3
Iesi 3
Jinan 3
Lausanne 3
Wuhan 3
Ōtsu 3
Aprilia 2
Bari 2
Bologna 2
Clearwater 2
Frosinone 2
Jinhua 2
Melbourne 2
Monte Vista 2
Mumbai 2
Nanning 2
Palo Alto 2
Phoenix 2
Putrajaya 2
Sesto San Giovanni 2
Taranto 2
Toronto 2
Verona 2
Albino 1
Amsterdam 1
Antalya 1
Apeldoorn 1
Ardabil 1
Astana 1
Athens 1
Auburn 1
Augusta 1
Bakersfield 1
Bangkok 1
Baotou 1
Bengaluru 1
Bergisch Gladbach 1
Cassano Magnago 1
Chaoyang 1
Charlotte 1
Chongqing 1
Corridonia 1
Dallas 1
Dhaka 1
Duncan 1
Durham 1
El Segundo 1
Farnborough 1
Florence 1
Fuzhou 1
Genoa 1
Grezzago 1
Hagen 1
Hebei 1
Istanbul 1
Jesi 1
Totale 10944
Nome #
Alexithymia and Plaque Psoriasis: Preliminary Investigation in a Clinical Sample of 250 Patients. 410
Pharmacokinetic drug evaluation of brodalumab for the treatment of psoriasis 382
HLA-C*06:02 Does Not Predispose to Clinical Response Following Long-Term Adalimumab Treatment in Psoriatic Patients: A Retrospective Cohort Study. 364
Tildrakizumab for treating psoriasis 361
Brodalumab for the treatment of psoriasis 353
Pharmacokinetic drug evaluation of dalbavancin for the treatment of skin infections 350
Role of HLA- C*06 in clinical response to ustekinumab: evidence from real-life in a large cohort of European patients. 349
What happened after the clinical trials: Long-term safety and efficacy of ustekinumab in daily clinical practice 348
Effect of anti IL-12/23 on body composition: results of bioelectrical impedance analysis in Caucasian psoriatic patients 340
Tofacitinib for the treatment of psoriasis 339
Secukinumab in moderate-to-severe plaque psoriasis: a multi-center, retrospective, real-life study up to 52 weeks observation 336
The Role of Pharmacogenetics in Chronic Plaque Psoriasis: Update of the Literature 332
Long-term ustekinumab therapy of psoriasis in patients with coexisting rheumatoid arthritis and Sjögren syndrome. Report of two cases and review of literature 320
New insight into the pathogenesis of nail psoriasis and overview of treatment strategies 318
A safety evaluation of guselkumab for the treatment of psoriasis 299
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate-to-severe plaque-type psoriasis: SUPREME study. 289
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. 284
A clinical case of severe disease burden: an erythrodermic psoriatic patient treated with secukinumab 272
Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study 264
Treating a Multidrug-Resistant Psoriatic HLA-C*18:01 Allele Carrier with Combination Ustekinumab Apremilast Therapy 259
Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature 259
Psoriasis in pregnancy: case series and literature review of data concerning exposure during pregnancy to ustekinumab 257
Photo-recall cutaneous reaction to gemcitabine 255
High-resolution HLA typing identifies a new 'super responder' subgroup of HLA-C*06:02-positive psoriatic patients: HLA-C*06:02/HLA-C*04, in response to ustekinumab 241
Spotlight on brodalumab in the treatment of plaque psoriasis: the evidence to date 234
Efficacy of sinecatechins 10% as proactive sequential therapy of external genital warts after laser CO2 ablative therapy: The PACT study (post-ablation immunomodulator treatment of condylomata with sinecatechins): a randomized, masked outcome assessment, multicenter trial 230
Pharmacotherapeutic management of psoriasis in adolescents and children 216
Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study 211
Successful treatment of psoriatic crumbly nails with ustekinumab 204
The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis 198
Skin immunity and its dysregulation in psoriasis 197
Therapeutic monitoring of male genital lichen sclerosus: usefulness of reflectance confocal microscopy 194
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study 189
Ustekinumab treatment for moderate-to-severe plaque psoriasis: eight-year real-life experience 183
In which patients the best efficacy of secukinumab? Update of a real-life analysis after 136 weeks of treatment with secukinumab in moderate-to-severe plaque psoriasis 156
Skin immunity and its dysregulation in atopic dermatitis, hidradenitis suppurativa and vitiligo 148
Clinical and histopathological characterization of eczematous eruptions occurring in course of anti IL-17 treatment: a case series and review of the literature 140
Real life experience of apremilast in psoriasis and arthritis psoriatic patients: preliminary results on metabolic biomarkers 138
Whole exome sequencing approach to childhood onset familial erythrodermic psoriasis unravels a novel mutation of CARD14 requiring unusual high doses of ustekinumab 110
Genetic variations in IL6 and IL12B decreasing the risk for psoriasis 94
IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis 90
Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab 90
A life with atopic dermatitis: the patient's point of view after a new hope with dupilumab 68
Characteristic of chronic plaque psoriasis patients treated with biologics in Italy during the COVID-19 pandemic: risk analysis from the PSO-BIO-COVID observational study 61
Italian guidelines in diagnosis and treatment of alopecia areata 59
Optimizing care for psoriatic patients requiring systemic therapies: how will COVID-19 disease transform risk perceptions? 59
Ustekinumab treatment of erythrodermic psoriasis occurring after physical stress: A report of two cases 57
Assessment of HLA Cw6 genotype and correlation to ustekinumab response in a large cohort of patients with moderate-to-severe psoriasis 57
Long-term ustekinumab treatment for refractory type I pityriasis rubra pilaris 56
Management of biological therapies for chronic plaque psoriasis during COVID-19 emergency in Italy 56
Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era 56
Bioelectrical impedance analysis to define an excess of body fat: evaluation in patients with psoriasis 52
HLA-Cw6 and other HLA-C alleles, as well as MICB-DT, DDX58 and TYK2 genetic variants associate with optimal response to anti-IL-17A treatment in patients with psoriasis 52
Use of guselkumab for the treatment of moderate-to-severe plaque psoriasis: a 1 year real-life study 51
Importance of genotyping patients for HLA-C*06:02: it provides not only pharmacogenetics implication in response to biologics drugs but also drug survival and drug-related costs information 51
HLA-C*06 and response to ustekinumab in Caucasian patients with psoriasis: Outcome and long-term follow-up 46
Linear psoriasis following the typical distribution of the sciatic nerve 40
Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts 38
Impact of secukinumab on patient-reported outcomes in moderate to severe plaque psoriasis: a review of clinical studies 38
HLACw6 predisposes to clinical response to IL12/23 blocker ustekinumab: Results of short- and long-term treatment in anti-TNF naïve patients 37
Efficacy and safety of ustekinumab in the treatment of patients affected by moderate-to-severe psoriasis 36
Human leucocyte antigen Cw6 predisposes to clinical response to the inlterleukin-12/23 blocker ustekinumab: results of long-term treatment 36
Ustekinumab for treatment of plaque psoriasis in a patient with down syndrome 36
Cw6 but not allele LCE3C_LCE3B deletion confers sensitivity to ustekinumab treatment in psoriasis 34
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study 34
HLA-C*18:01: A Rare Allele in the European Caucasian Population Coinciding with Difficult-to-Treat Plaque Psoriasis 32
Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study 25
Genetic variati ons in IL6 and IL12B as protecti ve markers for psoriasis Abstracts of the 2013 International Investigative Dermatology Meeting. May 8-11, 2013. Edinburgh, Scotland, United Kingdom 24
Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year 22
Genetic variations in IL6 and IL12B as protective markers for psoriasis 22
Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations 22
Efficacy of Tildrakizumab for the Treatment of Difficult-to-Treat Areas: Scalp, Nail, Palmoplantar and Genital Psoriasis 20
Diagnosis and management of cutaneous and anogenital lichen sclerosus: Recommendations from the Italian Society of Dermatology (SIDemaSt) 20
Potential role of HLA-Cw6 in clinical response to anti-tumour necrosis factor alpha and t-cell targeting agents in psoriasis patients 16
Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: data from the DA-COVID-19 registry 16
Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy 15
Safety of COVID-19 vaccines in patients with psoriasis undergoing therapy with anti-interleukin agents 15
Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations 15
HLA-C*06:02 allele can influence clinical efficacy of certolizumab pegol? 15
The value of genotyping patients for the presence of HLA-C in the personalized treatment of psoriasis 15
Patients Withdrawing Dupilumab Monotherapy for COVID-19-Related Reasons Showed Similar Disease Course Compared With Patients Continuing Dupilumab Therapy 14
Quality of life and psychological impact in patients with atopic dermatitis 14
null 12
Totale 12047
Categoria #
all - tutte 20396
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 20396

Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2017/201867 0000 00 00 00067
2018/20192067 1171058496 127140 215155 185219283341
2019/20204020 266251212336 367404 346349 484438311256
2020/20213113 313311310329 407431 351317 651668033
2021/2022908 47728118 3339 14135 675673246
2022/2023890 111877671 58228 8842 7123305
Totale 12047